NXTS:NASDAQNexentis Technologies Inc. Analysis
Data as of 2026-06-14 - not real-time
$4.80
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Technical outlook: The 20‑day SMA (≈4.95) now sits above the 50‑day SMA (≈4.72), signalling a brief upward creep, yet the 200‑day SMA (~16.3) remains far above the current price of $4.8, indicating a long‑term mismatch. The MACD histogram is negative and the MACD signal is flagged as bearish, while volume is on a decreasing trajectory, pointing to waning market interest.
Financial health: The company reports zero revenue, a substantial –$6.99 M EBITDA, and negative cash‑flow metrics (operating –$4.44 M, free –$2.55 M). Debt‑to‑equity soars at ~3.7, and ROE/ROA are negative, underscoring fragile economics. However, the price‑to‑book ratio (~0.27) and a low P/B suggest the stock is trading well below its book value.
Market sentiment & risk: The 30‑day volatility exceeds 130% and the beta (~1.37) exceeds the market, indicating high swing risk. The maximum drawdown of ~‑95% and an “Extreme Greed” index further amplify uncertainty.
R&D progress: Recent news highlights the MITOLINE‑powered platform and the MitoCareX bio milestone, suggesting incremental advances in the biotech pipeline, yet these developments remain pre‑clinical and do not offset the prevailing financial and technical concerns.
Financial health: The company reports zero revenue, a substantial –$6.99 M EBITDA, and negative cash‑flow metrics (operating –$4.44 M, free –$2.55 M). Debt‑to‑equity soars at ~3.7, and ROE/ROA are negative, underscoring fragile economics. However, the price‑to‑book ratio (~0.27) and a low P/B suggest the stock is trading well below its book value.
Market sentiment & risk: The 30‑day volatility exceeds 130% and the beta (~1.37) exceeds the market, indicating high swing risk. The maximum drawdown of ~‑95% and an “Extreme Greed” index further amplify uncertainty.
R&D progress: Recent news highlights the MITOLINE‑powered platform and the MitoCareX bio milestone, suggesting incremental advances in the biotech pipeline, yet these developments remain pre‑clinical and do not offset the prevailing financial and technical concerns.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 8/10
Key Factors
- bearish MACD
- decreasing volume
- high short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- ongoing R&D milestones
- low price‑to‑book ratio
- persistent negative cash flow
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- potential biotech commercialization
- substantial structural risk
- unresolved financial deficits
Key Metrics & Analysis
Financial Health
ROE-119.61%
ROA-37.56%
Debt/Equity3.68
P/B Ratio0.3
Op. Cash Flow$-4418000
Free Cash Flow$-2547500
Technical Analysis
TrendNeutral
RSI47.8
Support$4.02
Resistance$6.75
MA 20$4.95
MA 50$4.72
MA 200$16.27
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86
Valuation
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.37
Volatility139.93%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.